Claims for Patent: 9,884,050

Summary for Patent: 9,884,050

Title:	Inhibition of crystal growth of roflumilast
Abstract:	Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
Inventor(s):	Osborne; David W. (Fort Collins, CO)
Assignee:	Arcutis, Inc. (Menlo Park, CA)
Application Number:	15/676,356
Patent Claims:	1. A pharmaceutical composition comprising roflumilast and hexylene glycol. 2. The pharmaceutical composition according to claim 1, wherein said hexylene glycol is in an amount sufficient to inhibit roflumilast crystal growth or changes in particle size. 3. The pharmaceutical composition according to claim 1, wherein said hexylene glycol is in an amount of 0.1-20% w/w. 4. The pharmaceutical composition according to claim 1, wherein said roflumilast is in an amount of 0.005-2% w/w. 5. The pharmaceutical composition according to claim 1, further comprising pharmaceutically acceptable fillers, carriers and/or excipients. 6. The pharmaceutical composition according to claim 1, further comprising diethylene glycol monoethyl ether. 7. The pharmaceutical composition according to claim 5, wherein said pharmaceutically acceptable fillers, carriers and/or excipients are suitable for topical administration. 8. The pharmaceutical composition according to claim 1, wherein said composition is in the form of an emulsion, suspension, gel, spray, oil, ointment, fatty ointment, cream, paste, foam, transdermal patch or solution. 9. The pharmaceutical composition according to claim 1, comprising roflumilast, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben, and purified water. 10. The pharmaceutical composition according to claim 9, comprising the following components: TABLE-US-00003 roflumilast 0.5% w/w white petrolatum 10.0% w/w isopropyl palmitate 5.0% w/w cetearyl alcohol, dicetyl phosphate, 10.0% w/w and ceteth-10 phosphate hexylene glycol 2.0% w/w diethylene glycol monoethyl ether 25.0% w/w methylparaben 0.2% w/w propylparaben 0.05% w/w, and purified water q.s. ad 100 (47.25%). 11. The pharmaceutical composition according to claim 3, wherein said hexylene glycol is in an amount of 0.25-8% w/w. 12. The pharmaceutical composition according to claim 11, wherein said hexylene glycol is in an amount of 0.5-2% w/w.